Cardiac Blood-Based Biomarkers of Myocardial Stress As Predictors of Atrial Fibrillation Development in Patients With Embolic Stroke of Undetermined Source/Cryptogenic Stroke: A Systematic Review and Meta-Analysis

Overview

Journal J Clin Neurol

Specialty Neurology

Date 2024 Jan 3

PMID 38171502

Authors

Ana Sofia da Silva Justo

Sandra Micaela Abreu Nobrega

Ana Luisa Aires Silva

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: Undiagnosed atrial fibrillation (AF) is a major risk factor for stroke that can go unnoticed in individuals with embolic stroke of undetermined source (ESUS) or cryptogenic stroke (CS). Early detection is critical for stroke prognosis and secondary prevention. This study aimed to determine if blood biomarkers of myocardial stress can accurately predict AF in patients with ESUS/CS, which would allow the identification of those who would benefit from closer monitoring.

Methods: In February 2023 we performed a systematic date-unrestricted search of three databases for studies on patients with ESUS/CS who were subsequently diagnosed with AF. We examined the relationships between AF and serum myocardial stress markers such as brain natriuretic peptide (BNP), N-terminal-pro-BNP (NT-proBNP), midregional proatrial natriuretic peptide, and troponin.

Results: Among the 1,527 studies reviewed, 23 eligible studies involving 6,212 participants, including 864 with AF, were analyzed. A meta-analysis of 9 studies indicated that they demonstrated a clear association between higher NT-proBNP levels and an increased risk of AF, with adjusted and raw data indicating 3.06- and 9.03-fold higher AF risks, respectively. Lower NT-proBNP levels had a pooled negative predictive value of 91.7%, indicating the potential to rule out AF with an 8% false-negative rate.

Conclusions: Further research is required to fully determine the potential of biomarkers for AF detection after stroke, as results from previous studies lack homogeneity. However, lower NT-proBNP levels have potential in ruling out AF in patients with ESUS/CS. Combining them with other relevant biomarkers may enhance the precision of identifying patients who will not benefit from extended monitoring, which would optimize resource allocation and patient care.

References

Pala E, Pagola J, Juega J, Francisco-Pascual J, Bustamante A, Penalba A . B-type natriuretic peptide over N-terminal pro-brain natriuretic peptide to predict incident atrial fibrillation after cryptogenic stroke. Eur J Neurol. 2020; 28(2):540-547. DOI: 10.1111/ene.14579. View

Kneihsl M, Bisping E, Scherr D, Mangge H, Fandler-Hofler S, Colonna I . Predicting atrial fibrillation after cryptogenic stroke via a clinical risk score-a prospective observational study. Eur J Neurol. 2021; 29(1):149-157. PMC: 9292187. DOI: 10.1111/ene.15102. View

Yaghi S, Chang A, Ricci B, Jayaraman M, McTaggart R, Hemendinger M . Early Elevated Troponin Levels After Ischemic Stroke Suggests a Cardioembolic Source. Stroke. 2017; 49(1):121-126. DOI: 10.1161/STROKEAHA.117.019395. View

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

Rodriguez-Yanez M, Arias-Rivas S, Santamaria-Cadavid M, Sobrino T, Castillo J, Blanco M . High pro-BNP levels predict the occurrence of atrial fibrillation after cryptogenic stroke. Neurology. 2013; 81(5):444-7. DOI: 10.1212/WNL.0b013e31829d8773. View

Yaghi S, Kamel H, Elkind M . Atrial cardiopathy: a mechanism of cryptogenic stroke. Expert Rev Cardiovasc Ther. 2017; 15(8):591-599. PMC: 6092961. DOI: 10.1080/14779072.2017.1355238. View

Jaeschke R, Guyatt G, Sackett D . Users' guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. JAMA. 1994; 271(9):703-7. DOI: 10.1001/jama.271.9.703. View

Kamel H, Okin P, Longstreth Jr W, Elkind M, Soliman E . Atrial cardiopathy: a broadened concept of left atrial thromboembolism beyond atrial fibrillation. Future Cardiol. 2015; 11(3):323-31. PMC: 4868349. DOI: 10.2217/fca.15.22. View

Hart R, Diener H, Coutts S, Easton J, Granger C, ODonnell M . Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. 2014; 13(4):429-38. DOI: 10.1016/S1474-4422(13)70310-7. View

10.

Mueller C, McDonald K, de Boer R, Maisel A, Cleland J, Kozhuharov N . Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail. 2019; 21(6):715-731. DOI: 10.1002/ejhf.1494. View

11.

York M, Gupta D, Reynolds C, Farber-Eger E, Wells Q, Bachmann K . B-Type Natriuretic Peptide Levels and Mortality in Patients With and Without Heart Failure. J Am Coll Cardiol. 2018; 71(19):2079-2088. PMC: 5951190. DOI: 10.1016/j.jacc.2018.02.071. View

12.

Vera A, Cecconi A, Ximenez-Carrillo A, Ramos C, Martinez-Vives P, Lopez-Melgar B . A Comprehensive Model to Predict Atrial Fibrillation in Cryptogenic Stroke: The Decryptoring Score. J Stroke Cerebrovasc Dis. 2021; 31(1):106161. DOI: 10.1016/j.jstrokecerebrovasdis.2021.106161. View

13.

De Marchis G, Schneider J, Weck A, Fluri F, Fladt J, Foerch C . Midregional proatrial natriuretic peptide improves risk stratification after ischemic stroke. Neurology. 2018; 90(6):e455-e465. DOI: 10.1212/WNL.0000000000004922. View

14.

Cameron A, Cheng H, Lee R, Doherty D, Hall M, Khashayar P . Biomarkers for Atrial Fibrillation Detection After Stroke: Systematic Review and Meta-analysis. Neurology. 2021; 97(18):e1775-e1789. DOI: 10.1212/WNL.0000000000012769. View

15.

Dilaveris P, Kennedy H . Silent atrial fibrillation: epidemiology, diagnosis, and clinical impact. Clin Cardiol. 2017; 40(6):413-418. PMC: 6490532. DOI: 10.1002/clc.22667. View

16.

Oikonomou E, Zografos T, Papamikroulis G, Siasos G, Vogiatzi G, Theofilis P . Biomarkers in Atrial Fibrillation and Heart Failure. Curr Med Chem. 2017; 26(5):873-887. DOI: 10.2174/0929867324666170830100424. View

17.

Snyman S, Seder E, David-Muller M, Klein V, Doche E, Suissa L . Atrial Fibrillation Detected by Implantable Monitor in Embolic Stroke of Undetermined Source: A New Clinical Entity. J Clin Med. 2022; 11(19). PMC: 9571950. DOI: 10.3390/jcm11195740. View

18.

Maisel A, Mueller C, Adams Jr K, Anker S, Aspromonte N, Cleland J . State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail. 2008; 10(9):824-39. DOI: 10.1016/j.ejheart.2008.07.014. View

19.

Miyazaki Y, Toyoda K, Iguchi Y, Hirano T, Metoki N, Tomoda M . Atrial Fibrillation After Ischemic Stroke Detected by Chest Strap-Style 7-Day Holter Monitoring and the Risk Predictors: EDUCATE-ESUS. J Atheroscler Thromb. 2020; 28(5):544-554. PMC: 8193782. DOI: 10.5551/jat.58420. View

20.

Saver J . CLINICAL PRACTICE. Cryptogenic Stroke. N Engl J Med. 2016; 374(21):2065-74. DOI: 10.1056/NEJMcp1503946. View